Gamma camera probe developer Neoprobe of Dublin, OH, has signed an agreement with the University of California, San Diego that will enable the company to expand its Lymphoseek radiopharmaceutical into applications in ultrasound and optical imaging.
Neoprobe intends to develop the agent for use during biopsy procedures for the detection of lymph nodes in various tumor types, such as breast, melanoma, prostate, gastric, and colon cancers. The company is planning clinical trials for the radiopharmaceutical and intends to file a new drug application with the Food and Drug Administration in mid-2006.
The most recent deal with UCSD allows Neoprobe to develop Lymphoseek for ultrasound and optical applications. The company could develop receptor-binding compounds labeled with fluorescent or ultrasound contrast agents that can be detected with optical or ultrasound probes, avoiding the use of radioactive isotopes.
By AuntMinnie.com staff writers
April 21, 2005
Related Reading
Neoprobe gets new Quantix/OR clearance, February 15, 2005
Neoprobe extends Japanese distribution deal, August 25, 2004
Neoprobe reports Q1 results, May 13, 2004
Neoprobe trims losses in 2003, March 9, 2004
Neoprobe hires Linder, October 27, 2003
Copyright © 2005 AuntMinnie.com
